Serologically Active, Clinically Stable Systemic Lupus Erythematosus
Launched by NYU LANGONE HEALTH · Nov 3, 1999
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
In lupus, serial evaluation of dsDNA antibody titers and complement (C3 and C4) in blood samples have been useful in assessing disease activity in patients. High levels of C3a, a split product of C3, are particularly sensitive and reflective of lupus flares. Our study looks at whether elevations in C3a can predict lupus flares and how C3a compares with other conventional blood indicators such as dsDNA antibody, C3, C4, and CH50. The utility of serial anti-dsDNA antibodies and complement measurements in clinical decision-making for people with systemic lupus erythematosus (SLE) remains contr...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Meets ACR criteria for SLE
- • Inactive or stable in lupus activity
- • History of positive dsDNA
- • Current prednisone dose no more than 15 mg daily
- Exclusion Criteria:
- • Active infections
- • Poorly controlled diabetes mellitus
- • Pregnancy
- • Uncontrolled hypertension
About Nyu Langone Health
NYU Langone Health is a premier academic medical center located in New York City, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a leading sponsor of clinical trials, NYU Langone Health integrates cutting-edge scientific inquiry with patient-centered care, striving to develop new therapies and improve health outcomes across a wide range of medical conditions. The institution is dedicated to fostering collaboration among researchers, clinicians, and patients, ensuring rigorous adherence to ethical standards and regulatory guidelines in all clinical research initiatives. By leveraging its extensive resources and expertise, NYU Langone Health aims to contribute significantly to the advancement of medical knowledge and the enhancement of patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bronx, New York, United States
New Hyde Park, New York, United States
New York, New York, United States
Patients applied
Trial Officials
Steven B. Abramson
Principal Investigator
Hospital for Joint Diseases
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials